Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Zimmer Biomet has a consensus “Hold” rating from 22 brokerages: 14 holds, six buys and two sells. The average 12-month price target is $103, compared with a recent share price of $94.27.
• The company exceeded quarterly expectations, reporting $2.07 in adjusted EPS and $2.18 billion in revenue, with revenue up 4.8% year over year. Analysts project approximately $8.54 in EPS for the current year.
• Institutional investors own 88.89% of the stock, while insiders own 1.28%; two insiders recently sold shares. Zimmer Biomet also declared a quarterly dividend of $0.24 per share, representing a 1.0% annualized yield.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) have been given a consensus recommendation of "Hold" by the twenty-two brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $103.00.

Several analysts have recently issued reports on the stock. Zacks Research raised shares of Zimmer Biomet from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 25th. UBS Group restated a "buy" rating and issued a $120.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. Robert W. Baird set a $104.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Citigroup decreased their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating for the company in a research report on Thursday, May 28th. Finally, Sanford C. Bernstein boosted their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a research note on Thursday, August 6th.

Insider Transactions at Zimmer Biomet

In other news, insider Kevin R. Thornal sold 5,691 shares of the business's stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Chad F. Phipps sold 3,000 shares of the company's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider owned 65,231 shares in the company, valued at $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Zimmer Biomet in the 2nd quarter valued at $1,344,282,000. Primecap Management Co. CA purchased a new stake in shares of Zimmer Biomet during the 2nd quarter worth $328,578,000. Norges Bank acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $221,234,000. Bank of America Corp DE acquired a new position in shares of Zimmer Biomet during the second quarter worth $187,480,000. Finally, Franklin Resources Inc. increased its holdings in Zimmer Biomet by 43.2% in the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider's stock valued at $601,204,000 after buying an additional 2,017,857 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Stock Down 1.1%

NYSE:ZBH opened at $94.27 on Tuesday. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The stock's fifty day moving average is $96.23 and its two-hundred day moving average is $91.32. Zimmer Biomet has a 52 week low of $79.12 and a 52 week high of $106.88. The stock has a market capitalization of $17.98 billion, a price-to-earnings ratio of 22.94, a price-to-earnings-growth ratio of 1.80 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts' expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company's revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts anticipate that Zimmer Biomet will post 8.54 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet's payout ratio is presently 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc NYSE: ZBH is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.